Exelixis, Inc. (EXEL) Up 4.8% — Should I Move From Watching to Buying?
Exelixis, Inc. (EXEL) surged 4.81% in the latest session, finishing at $45.71 on the NASDAQ after closing the prior day at $43.61. The move marked a strong performance on the day, with the stock gaining $2.10 and pushing decisively higher in bullish activity. With EXEL advancing into the mid-$40s, the action reflects steady momentum as buyers continued to add exposure and the stock gained ground from the previous close.
Trading volume totaled 1,851,567 shares, running below the 90-day average of 2,671,202. Even with lighter-than-usual turnover, the price action remained constructive, suggesting the advance held up without requiring outsized participation. From a longer-term perspective, EXEL is now within striking distance of its 52-week high of $49.62 (set on 06/23/2025), sitting about $3.91 — roughly 7.9% — below that level. That keeps the stock in an upward-leaning range, with the recent push narrowing the gap to its peak and reinforcing the current trend.
Within the broader Health Care sector, EXEL’s move stood out as a notable gain, offering a more forceful upswing than the kind of incremental moves investors often see across the broader peer group. The combination of a sizable one-day percentage jump and a close that held near session highs puts the focus on continued strength and the potential for follow-through, as the stock remains positioned closer to the top of its 52-week band.
Why Exelixis, Inc. Price is Moving Higher
Exelixis, Inc. is getting a lift from renewed optimism around its oncology pipeline, led by detailed results from the pivotal phase 3 STELLAR-303 trial for zanzalintinib. For investors, late-stage trial readouts can act as major sentiment drivers because they help clarify clinical differentiation and potential commercial runway. In biotech, that kind of visibility often attracts incremental interest from growth-oriented funds and healthcare specialists looking to position ahead of potential regulatory and partnering milestones—supporting bullish sentiment even without a single, one-day headline catalyst.
Momentum is also being reinforced by Exelixis’ financial flexibility. The company’s $1.65 billion cash and marketable securities position provides a meaningful cushion to fund development programs and absorb volatility that can hit the biotech group. On top of that, the authorized $750 million share repurchase program—targeted for completion by the end of 2026—adds a shareholder-friendly element that can help underpin demand when investors see management willing to commit capital to its own stock.
Fundamentals help explain why buyers are showing up: revenue growth of 5.63% signals ongoing business expansion, while a 33.72% profit margin highlights strong operating leverage for a company still investing in R&D. In a Health Care tape where large-cap names often anchor institutional allocations, profitable biopharma names with credible late-stage catalysts can stand out, helping keep enthusiasm constructive as momentum builds.
What is the Exelixis, Inc. Rating - Should I Buy?
Weiss Ratings assigns EXEL a B rating. Current recommendation is Buy. For investors looking for a Health Care name with a favorable balance of opportunity and risk control, that overall grade is supported by standout fundamentals, particularly in business momentum and financial strength.
A key driver is operational quality: Exelixis earns the Excellent Growth Index and the Excellent Efficiency Index, a combination that favors companies expanding the business while maintaining disciplined execution. Recent revenue growth of 5.63% pairs with a 33.72% profit margin, indicating that growth is coming with meaningful profitability. The company’s 35.53% return on equity further reinforces the view that capital is being put to work effectively, a positive backdrop for long-term compounding.
Risk and resilience also look constructive. The Excellent Solvency Index signals balance-sheet strength, which can matter in biotech and pharma where pipelines and timing can create uneven results. On the market-performance side, the Good Total Return Index and Good Volatility Index point to a profile that has been more consistent than many higher-beta alternatives, while still offering participation when sentiment improves. Valuation is not stretched on a forward basis either, with a P/E (forward) of 15.72.
Within Health Care sector, EXEL compares well with Amgen Inc. (AMGN, B) and United Therapeutics Corporation (UTHR, B), and it sits ahead of Gilead Sciences, Inc. (GILD, B-) and Eli Lilly and Company (LLY, B-). It also remains competitive alongside Johnson & Johnson (JNJ, B+), positioning EXEL as a credible Buy-rated option in a sector crowded with quality names.
About Exelixis, Inc.
Exelixis, Inc. (EXEL) is a Health Care company in the Pharmaceuticals, Biotechnology and Life Sciences industry focused on discovering, developing, and commercializing targeted cancer therapies. The company is best known for CABOMETYX (cabozantinib), an oral tyrosine kinase inhibitor used across multiple tumor types, including renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ, a related formulation for medullary thyroid cancer. Exelixis also markets COTELLIC (cobimetinib), a MEK inhibitor used in combination regimens for certain melanoma patients. With a concentrated focus in oncology, Exelixis operates with an integrated model that spans clinical development, regulatory execution, and commercial capabilities.
A core strength of Exelixis is its sustained commitment to expanding the clinical utility of cabozantinib through additional indications, line extensions, and combination approaches, including work alongside immune-oncology agents. Its deep expertise in kinase biology and translational research supports a pipeline designed to address areas of unmet medical need, where targeted mechanisms can deliver meaningful clinical benefit. In the competitive oncology landscape, the company’s established presence in kidney cancer and liver cancer provides a durable platform, while ongoing research programs and collaborations help diversify opportunities across solid tumors. This combination of marketed oncology brands, a development-stage pipeline, and specialized know-how positions Exelixis as a notable participant within the biopharmaceutical cancer-treatment market.
Investor Outlook
With a Weiss Rating of B (Buy), Exelixis, Inc. (EXEL) is favorably positioned for potential continued gains, especially if momentum holds above recent breakout levels and the broader Health Care backdrop remains supportive. Investors will want to watch whether the stock can defend key support on pullbacks while sustaining the operating factors that underpin the Buy-grade risk/reward profile. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--